In a win for the pharmaceutical industry, the Food and Drug Administration has indefinitely delayed implementing a final rule that would give the agency greater leeway to police off-label marketing.

This marks the second time in the past year the agency has delayed the rule, which was scheduled to go into effect in March, and follows alarm expressed by drug makers that the proposed rule would harm public health and chill “valuable scientific speech.”

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • One might observe that Commissioner Scott G may be picking his battles – may be, of course is the operative phrase. once again, time will tell.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy